Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:CDXSNASDAQ:LXRXNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$2.70-4.3%$2.13$1.38▼$19.69$68.33M1.58600,995 shs651,633 shsCDXSCodexis$2.26-1.7%$2.73$1.90▼$6.08$187.21M2.35662,366 shs355,246 shsLXRXLexicon Pharmaceuticals$0.71+0.7%$0.49$0.28▼$2.45$174.43M1.026.46 million shs8.26 million shsSGMOSangamo Therapeutics$0.79-3.4%$0.84$0.30▼$3.18$176.85M1.578.52 million shs1.98 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-4.26%+29.81%+61.68%-24.37%-63.61%CDXSCodexis-1.74%+7.11%-19.86%-53.97%-19.29%LXRXLexicon Pharmaceuticals+0.71%+38.96%+115.32%-28.44%-55.73%SGMOSangamo Therapeutics-3.42%+11.54%-6.86%-32.16%+59.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.3765 of 5 stars3.11.00.04.61.91.70.6CDXSCodexis3.3035 of 5 stars3.31.00.02.52.91.70.6LXRXLexicon Pharmaceuticals2.8492 of 5 stars4.22.00.00.02.61.70.6SGMOSangamo Therapeutics2.1674 of 5 stars3.34.00.00.01.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$8.75224.07% UpsideCDXSCodexis 2.67Moderate Buy$8.33268.73% UpsideLXRXLexicon Pharmaceuticals 2.40Hold$3.67417.60% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$5.17556.50% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, CDXS, SGMO, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/7/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/18/2025SGMOSangamo TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$2.00 ➝ $2.003/12/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $3.003/12/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/7/2025LXRXLexicon PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $6.003/5/2025LXRXLexicon PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/4/2025LXRXLexicon PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$2.00 ➝ $1.003/3/2025LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M0.66N/AN/A($7.78) per share-0.35CDXSCodexis$59.35M3.15N/AN/A$1.24 per share1.82LXRXLexicon Pharmaceuticals$31.08M5.61N/AN/A$0.38 per share1.86SGMOSangamo Therapeutics$57.80M3.06$0.03 per share30.42$0.47 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$10.68N/AN/AN/A-145.89%N/A-85.68%5/6/2025 (Estimated)CDXSCodexis-$76.24M-$0.90N/AN/AN/A-96.35%-71.56%-38.00%5/1/2025 (Estimated)LXRXLexicon Pharmaceuticals-$177.12M-$0.64N/AN/AN/A-4,109.41%-107.38%-64.09%5/1/2025 (Estimated)SGMOSangamo Therapeutics-$257.83M-$0.52N/AN/AN/A-257.87%-264.16%-107.24%5/8/2025 (Estimated)Latest AGEN, CDXS, SGMO, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SGMOSangamo Therapeutics-$0.12N/AN/AN/A$7.90 millionN/A5/6/2025Q1 2025AGENAgenus-$1.72N/AN/AN/A$26.38 millionN/A5/1/2025Q1 2025CDXSCodexis-$0.20N/AN/AN/A$10.38 millionN/A5/1/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10N/AN/AN/A$1.26 millionN/A3/17/2025Q4 2024SGMOSangamo Therapeutics-$0.09-$0.11-$0.02-$0.11$11.70 million$7.55 million3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 million3/6/2025Q4 2024LXRXLexicon Pharmaceuticals-$0.11-$0.09+$0.02-$0.09$6.48 million$26.55 million2/27/2025Q4 2024CDXSCodexis-$0.04-$0.13-$0.09-$0.13$27.41 million$21.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19CDXSCodexis0.393.213.15LXRXLexicon Pharmaceuticals0.567.457.43SGMOSangamo TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%CDXSCodexis78.54%LXRXLexicon Pharmaceuticals74.70%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipAGENAgenus4.60%CDXSCodexis2.10%LXRXLexicon Pharmaceuticals6.80%SGMOSangamo Therapeutics2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44025.31 million22.38 millionOptionableCDXSCodexis25082.84 million79.67 millionOptionableLXRXLexicon Pharmaceuticals140246.24 million229.49 millionOptionableSGMOSangamo Therapeutics480224.71 million202.81 millionOptionableAGEN, CDXS, SGMO, and LXRX HeadlinesRecent News About These CompaniesSangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Renaissance Technologies LLCApril 26 at 3:39 AM | marketbeat.comAnalyzing Sangamo Therapeutics (NASDAQ:SGMO) and Vericel (NASDAQ:VCEL)April 23 at 2:06 AM | americanbankingnews.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 10.12%April 21, 2025 | aaii.comWasatch Advisors LP Decreases Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)April 19, 2025 | marketbeat.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 5.89%April 18, 2025 | aaii.comQ1 EPS Forecast for Sangamo Therapeutics Raised by AnalystApril 12, 2025 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 12, 2025 | marketbeat.comResearch Analysts Set Expectations for SGMO Q4 EarningsApril 11, 2025 | marketbeat.comSangamo Therapeutics' (SGMO) Buy Rating Reaffirmed at HC WainwrightApril 9, 2025 | marketbeat.comLilly, Sangamo Enter Capsid License AgreementApril 8, 2025 | contractpharma.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 15.51%April 8, 2025 | aaii.comLilly Throws Sangamo a Lifeline with Pact Worth Potential $1.4B+April 5, 2025 | biospace.comAnother rebound as Sangamo inks $1.4B capsid deal with LillyApril 5, 2025 | bioworld.comSangamo Thera enters critical deal with LillyApril 5, 2025 | thepharmaletter.comLilly throws lifeline to Sangamo with $1.4bn licensing dealApril 4, 2025 | pharmaphorum.comSangamo up 53% to 95c after announcing license pact with Eli LillyApril 4, 2025 | markets.businessinsider.comSangamo announces capsid license agreement with Eli LillyApril 3, 2025 | markets.businessinsider.comShares of Sangamo Therapeutics Rally on Licensing Deal With Eli LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics Enters Capsid License Agreement With LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics stock soars on Lilly licensing dealApril 3, 2025 | investing.comSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous SystemApril 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialIONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadBy Leo Miller | April 12, 2025View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadAGEN, CDXS, SGMO, and LXRX Company DescriptionsAgenus NASDAQ:AGEN$2.70 -0.12 (-4.26%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.77 +0.07 (+2.74%) As of 04/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Codexis NASDAQ:CDXS$2.26 -0.04 (-1.74%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.30 +0.04 (+1.77%) As of 04/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Lexicon Pharmaceuticals NASDAQ:LXRX$0.71 +0.01 (+0.71%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.71 +0.01 (+0.79%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Sangamo Therapeutics NASDAQ:SGMO$0.79 -0.03 (-3.42%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.79 +0.00 (+0.13%) As of 04/25/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
